Lancet Haematology publishes data demonstrating Sandoz Rixathon® (biosimilar rituximab) matches efficacy and safety of reference biologic

  • Lancet Haematology publishes data from ASSIST-FL study of Sandoz Rixathon®, in patients with previously untreated advanced follicular lymphoma
  • ASSIST-FL, results of which were first announced in December 2017, achieved its primary endpoint1
  • Rixathon® received European Commission approval for use in all indications of the reference biologic in June 2017 2,3

Holzkirchen, August 29, 2017 – Lancet Haematology has published data from the ASSIST-FL trial demonstrating that the efficacy and safety of …

/by

Sandoz expands partnership with World Child Cancer, to help children access treatment in four developing countries

  • Expanded partnership to help “even the odds” of survival for children with cancer in the Philippines, Myanmar, Mexico and Ghana
  • In developed countries, the survival rate for childhood cancer is 80%, while in developing countries it can be as low as 10%
  • Sandoz is committed to working with key stakeholders to pioneer novel ways of expanding access to healthcare

The digital press release with multimedia content can be accessed here: 

…

/by

Q2 results confirm full year guidance. Strong pipeline results underpin potential of several highly innovative products

  • Net sales in line with prior year (0% cc[1], -2% USD), as growth drivers offset Gleevec/Glivec Gx impact:
    • Cosentyx (USD 490 million, +90% cc) continues strong growth in all three indications
    • Entresto (USD 110 million) grew steadily driven by improved access and US sales force expansion
    • Excluding Gleevec/Glivec, Oncology grew 9% (cc), driven by Promacta, Tafinlar + Mekinist  and Jakavi
    • Sandoz declined 4% (cc) mainly impacted by increased US pricing pressure
    • Alcon grew 3% (cc) driven by Surgical (+3 …
/by

Sandoz receives approval in Europe for Erelzi® (biosimilar etanercept) to treat multiple inflammatory diseases

  • European Commission approves Sandoz Erelzi® to treat immunological diseases such as rheumatoid arthritis, psoriasis, and psoriatic arthritis
  • Approval of Erelzi provides more treatment options for healthcare professionals and patients and opens another chapter in the Sandoz immunology portfolio
  • Sandoz now has five biosimilars approved in Europe, including biosimilars of some of the world’s leading blockbuster biologics1

Holzkirchen, June 27, 2017 — Sandoz, a Novartis …

/by

Sandoz receives approval in Europe for Rixathon® (biosimilar rituximab) to treat blood cancers and immunological diseases

  • European Commission approves Sandoz Rixathon® to treat blood cancers and immunological diseases.
  • Approval expected to broaden patient access to biologics and enable budget-constrained healthcare systems to reallocate resources to other healthcare priorities.
  • Sandoz now has four biosimilars approved in Europe — more than any other company.1

Holzkirchen, June 19, 2017 — Sandoz, a Novartis division, and the pioneer and global leader in biosimilars, announced today that the European …

/by

Sandoz receives approval in Europe for Rixathon® (biosimilar rituximab) to treat blood cancers and immunological diseases

  • European Commission approves Sandoz Rixathon® to treat blood cancers and immunological diseases.
  • Approval expected to broaden patient access to biologics and enable budget-constrained healthcare systems to reallocate resources to other healthcare priorities.
  • Sandoz now has four biosimilars approved in Europe — more than any other company.1

Holzkirchen, June 19, 2017 — Sandoz, a Novartis division, and the pioneer and global leader in biosimilars, announced today that the European …

/by

FDA accepts Sandoz regulatory submission for a generic version of Advair Diskus®

  • FDA accepts Sandoz ANDA for substitutable generic version of Advair Diskus®
  • Sandoz believes its combination product will offer asthma and COPD patients same safety and efficacy as reference medicine
  • Sandoz looks forward to working with FDA to drive access to this treatment option

Holzkirchen, June 15, 2017- Sandoz today announced that the US Food and Drug Administration (FDA) has accepted its Abbreviated New Drug Application for fluticasone propionate / salmeterol combination product, a substitutable …

/by

FDA accepts Sandoz regulatory submission for a generic version of Advair Diskus®

  • FDA accepts Sandoz ANDA for substitutable generic version of Advair Diskus®
  • Sandoz believes its combination product will offer asthma and COPD patients same safety and efficacy as reference medicine
  • Sandoz looks forward to working with FDA to drive access to this treatment option

Holzkirchen, June 15, 2017- Sandoz today announced that the US Food and Drug Administration (FDA) has accepted its Abbreviated New Drug Application for fluticasone propionate / salmeterol combination product, a substitutable …

/by

US Supreme Court rules in favor of Sandoz in biosimilars case, enabling earlier access to potentially life-saving medicines

  • US Supreme Court rules that six months’ notice of commercial marketing can be given prior to FDA approval in Sandoz vs. Amgen
  • Justices also provided much needed clarity on the patent litigation process, often referred to as the ‘patent dance’
  • As the first company to gain approval for and launch a biosimilar under the BPCIA’s new regulatory pathway, Sandoz continues to pioneer the path forward for these high-quality, cost-effective medicines in the US

Holzkirchen, 13 June 2017 – Sandoz, a Novartis division, today announced that the Supreme …

/by

US Supreme Court rules in favor of Sandoz in biosimilars case, enabling earlier access to potentially life-saving medicines

  • US Supreme Court rules that six months’ notice of commercial marketing can be given prior to FDA approval in Sandoz vs. Amgen
  • Justices also provided much needed clarity on the patent litigation process, often referred to as the ‘patent dance’
  • As the first company to gain approval for and launch a biosimilar under the BPCIA’s new regulatory pathway, Sandoz continues to pioneer the path forward for these high-quality, cost-effective medicines in the US

Holzkirchen, 13 June 2017 – Sandoz, a Novartis division, today announced that the Supreme …

/by